PMID- 26118632
OWN - NLM
STAT- MEDLINE
DCOM- 20160502
LR  - 20150720
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 27
IP  - 2
DP  - 2015 Aug
TI  - Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic 
      hepatitis B infection.
PG  - 238-43
LID - S1567-5769(15)00310-0 [pii]
LID - 10.1016/j.intimp.2015.06.019 [doi]
AB  - Dendritic cells (DCs) are multifunctional cells that initiate adaptive immune 
      responses. Patients with chronic hepatitis B virus (HBV) infection have reduced 
      numbers of DCs which may be functionally impaired, a defect that may contribute 
      to viral persistence. Autologous DC-based immunotherapy is considered to be a 
      treatment option for chronic HBV infection (CHB). We evaluated the therapeutic 
      efficacy of HBV-pulsed DCs in combination with the antiviral drug entecavir in 
      patients with CHB. Eighty patients were divided into four groups: HBV-pulsed DCs 
      only, HBV-pulsed DCs plus entecavir, entecavir only, and an untreated control 
      group. Patients on combination therapy exhibited greater antiviral responses than 
      patients on either monotherapy. The combination of HBV-pulsed DCs and entecavir 
      resulted in the largest reduction in serum viral DNA levels and the highest 
      percentage of virologic response. In addition, combination therapy resulted in 
      viral e antigen (HBeAg) loss and seroconversion. These results suggest that the 
      combination of HBV-pulsed autologous DCs and entecavir could be therapeutically 
      advantageous for patients with CHB.
CI  - Copyright (c) 2015 Elsevier B.V. All rights reserved.
FAU - Wei, Mei-Juan
AU  - Wei MJ
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Pan, Xing-Nan
AU  - Pan XN
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Wei, Kai-Peng
AU  - Wei KP
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Li, Xu-Hong
AU  - Li XH
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Liu, Xiao-Long
AU  - Liu XL
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Zhang, Xiao-Man
AU  - Zhang XM
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Jiang, Ya-Ling
AU  - Jiang YL
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Zhang, Chun-Yu
AU  - Zhang CY
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
FAU - Shen, Jian-Kun
AU  - Shen JK
AD  - Clinical Liver Center, 180th Hospital of People's Liberation Army, Quanzhou 
      362000, Fujian Province, China.
LA  - eng
SI  - ChiCTR/CHICTR-ONRC-14004393
PT  - Clinical Trial
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150625
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Antiviral Agents)
RN  - 0 (DNA, Viral)
RN  - 0 (Hepatitis B e Antigens)
RN  - 5968Y6H45M (entecavir)
RN  - 5Z93L87A1R (Guanine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Cell- and Tissue-Based Therapy
MH  - Combined Modality Therapy
MH  - DNA, Viral/blood
MH  - *Dendritic Cells/immunology/virology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Guanine/*analogs & derivatives/therapeutic use
MH  - Hepatitis B e Antigens
MH  - *Hepatitis B virus
MH  - Hepatitis B, Chronic/blood/*therapy/virology
MH  - Humans
MH  - Immunotherapy
MH  - Male
MH  - Middle Aged
MH  - Seroconversion
MH  - Young Adult
OTO - NOTNLM
OT  - Chronic hepatitis B
OT  - Dendritic cells
OT  - HBV-pulsed DC
OT  - Immunotherapy
EDAT- 2015/06/30 06:00
MHDA- 2016/05/03 06:00
CRDT- 2015/06/30 06:00
PHST- 2015/02/15 00:00 [received]
PHST- 2015/06/15 00:00 [revised]
PHST- 2015/06/15 00:00 [accepted]
PHST- 2015/06/30 06:00 [entrez]
PHST- 2015/06/30 06:00 [pubmed]
PHST- 2016/05/03 06:00 [medline]
AID - S1567-5769(15)00310-0 [pii]
AID - 10.1016/j.intimp.2015.06.019 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2015 Aug;27(2):238-43. doi: 10.1016/j.intimp.2015.06.019. 
      Epub 2015 Jun 25.